Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Patients with Plasmodium vivax malaria are treated with primaquine to prevent relapse infections. We report primaquine failure in a patient with 3 relapses without any possibility of re-infection. Using whole genome sequencing of the relapsing parasite isolates, we identified single nucleotide variants as candidate molecular markers of resistance.

Original publication

DOI

10.3201/eid1905.121852

Type

Journal article

Journal

Emerg Infect Dis

Publication Date

05/2013

Volume

19

Pages

802 - 805

Keywords

Plasmodium vivax, genetics, malaria, parasites, primaquine, relapse, Adult, Antimalarials, Biotransformation, Chloroquine, Drug Tolerance, Genome, Protozoan, High-Throughput Nucleotide Sequencing, Humans, Malaria, Vivax, Male, Plasmodium vivax, Polymorphism, Single Nucleotide, Primaquine, Recurrence, Sequence Analysis, DNA